RxDoctor Payments Data

John Tran, DO

Family Medicine · Altus, OKNPI 1285677203

Payments from drug & device makers

$1,916in general payments, 2019–2025

Across 117 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$316
  • AstraZeneca$310
  • GSK$215
  • Boehringer Ingelheim$176
  • Pfizer$128
  • Novo Nordisk$118
  • plus $654 from 12 others

What the payments were for

  • Food & beverage$1,916100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,916 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$2,180
Medicare patients
14
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$119,342
JardianceEmpagliflozin88$63,694
OzempicSemaglutide61$57,969
TrulicityDulaglutide58$54,952
NuplazidPimavanserin Tartrate12$29,827
XareltoRivaroxaban53$26,930
TradjentaLinagliptin39$24,383
MyrbetriqMirabegron39$20,134
Combivent RespimatIpratropium/Albuterol Sulfate26$18,550
FarxigaDapagliflozin Propanediol26$14,866
LinzessLinaclotide75$13,512
MounjaroTirzepatide12$12,504
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,491
JanuviaSitagliptin Phosphate11$11,437
Lantus SolostarInsulin Glargine,hum.Rec.Anlog118$10,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$119,342181 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$176$106,627153 claims
Lilly USA, LLCTrulicity, Mounjaro$316$67,45670 claims
Novo NordiskOzempic$118$57,96961 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$215$23,93152 claims
AbbVieLinzess, Vraylar$31$22,90987 claims
AstraZenecaFarxiga, Breztri Aerosphere$310$22,17438 claims
MerckJanuvia$35$11,43711 claims
NovartisExelon$96$8,73512 claims
Sumitomo Pharma America, Inc.Gemtesa$19$3,87714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Altus

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →